ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1994

Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus : A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual

Yasser M. El Miedany1, Sami Bahlas2, Maha El Gaafary3, Sally Youssef4 and Ihab Ahmed5, 1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, 2Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, 3Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, 4Rheumatology and Rehabilitation Departmennt, Ain Shams University, Cairo, Egypt, 5Medicine, Cairo University, Cairo, Egypt

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Electronic Health Record, SLE and patient outcomes

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: ACR Plenary Session II: Discovery 2015

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Patient reported outcomes measures (PROMs) are changing the landscape in rheumatology care. Electronic PROMs (ePROMs) is a new patient-centric model of collaboration that fully engages patients in the decision making and governance to optimize controlling their disease activity and its management.

Objectives. To assess the value of ePROMs in the assessment and management of SLE disease activity flares observed over a 24-month period; its association with adherence to therapy as well as organ damage adjusted for potential confounding factors.

Methods:

A randomized, controlled crossover study carried out over 24-month duration. 147 SLE patients meeting the revised ACR criteria were enrolled. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) whereas organ damage was scored using the SLICC/ACR Damage Index (SDI). In the first 12-month, the patients were assessed once every 3-months. Prior to their assessment in the clinic, each patient completed a PROMs questionnaire (paper format) [1]. Flare was defined as an increase ≥4 points in the SLEDAI between two clinic visits. At 12-months, the patients were randomized into a cohort of 73 patients who continued their care in the same style and 74 patients who completed an online ePROMs questionnaire on monthly basis for another 12-month period. The patients were given an appointment in an SLE hot clinic should their SLEDAI shows an increase of more than three points, management was adjusted accordingly. Otherwise every patient was seen every 3-months. The data captured were then retrospectively analysed at the end of the 24-month study period to determine the association between the number of flares and damage accrual. Adherence to therapy was also assessed at the end of the study.

Results:

At the end of the first year of the study, the mean of SLEDAI and SDI were 8.72 (6.1) and 1.9 (2.2) respectively. At the end of the second year the mean SLEDAI and SDI in the ePROMs cohort was 3.1 (2.6) and  1.2 (1.3) respectively, whereas in the control group the SDI an SLEDAI mean was 7.63 (6.7) and 1.8 (2.3) respectively (p< 0.01). Adjusting for possible confounding variables, the number of flares, regardless of their severity, was associated with damage accrual (OR 2.03, 95% CI 1.34 to 2.83, p<0.001). Adherence to therapy was significantly (p<0.1) higher in the ePROMs group whereas stopping DMARDs for intolerability was significantly (p<0.01) higher in the control group at 24-months of treatment.

Conclusion:

ePROMs has a potential disease modifying effect as it facilitated close monitoring of disease activity with an option of management escalation whenever indicated. Disease activity as measured by SLEDAI over a 24-month observation period predicted the risk of subsequent organ damage independently of other known risk factors.

Reference:

1. El Miedany Y et al. Ann Rheum Dis 2013; 72(Suppl3):484


Disclosure: Y. M. El Miedany, None; S. Bahlas, None; M. El Gaafary, None; S. Youssef, None; I. Ahmed, None.

To cite this abstract in AMA style:

El Miedany YM, Bahlas S, El Gaafary M, Youssef S, Ahmed I. Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus : A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/electronic-patient-reported-outcome-measures-in-systemic-lupus-erythematosus-a-potential-disease-modifying-impact-on-the-management-of-disease-activity-flares-and-damage-accrual/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/electronic-patient-reported-outcome-measures-in-systemic-lupus-erythematosus-a-potential-disease-modifying-impact-on-the-management-of-disease-activity-flares-and-damage-accrual/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.